Circulating Fibroblast Growth Factor 21 and Total Testosterone in Type 2 Diabetes Mellitus Men With Coronary Heart Disease

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Aug 1

PMID 35909513

Authors

Yufeng Mei

Yongnan Lyu

Zhiming Zhao

Yan Li

Affiliations

Soon will be listed here.

Abstract

Background: Fibroblast growth factor 21 increased in population with type 2 diabetes mellitus (T2DM), while serum total testosterone often decreased in men with T2DM. This study aimed to investigate the relationship between the prevalence of coronary artery disease (CAD) and circulating FGF21 concentrations and serum testosterone in T2DM men.

Methods: 490 men with T2DM from January 2021 to December 2021 were recruited from the Renmin Hospital of Wuhan University, and they were divided into CAD group (n=248) and control group (n=242). FGF21 were determined based on ELISA principle and serum total testosterone was measured in a liquid chromatography mass spectrometer LC/MS-8050 (Shimadzu, Japan). Logistic and restricted cubic spline analyses were performed to examine the association between the prevalence of CAD and circulating FGF21 concentrations and serum testosterone in T2DM men. The receiver operating curve (ROC) analysis was used to explore the predictive performance.

Results: Circulating FGF21 levels were higher in T2DM men with CAD compared with those without CAD [214.63 (121.82, 348.64) pg/ml vs 166.55 (94.81,254.48) pg/ml, <0.001], while serum total testosterone was lower [3.08 ± 0.07 ng/ml vs 3.76 ± 0.09 ng/ml, p<0.001]. The fully adjusted odds ratio (OR) and 95% confidence intervals (95%CI) was 2.956(1.409,6.201) for those in quartile 4 of FGF21 versus quartile 1 and the fully adjusted OR (95%CI) was 0.346(0.174,0.686) for those in quartile 4 of testosterone versus quartile 1. The receiver operating curve (ROC) analysis showed that the area under the curve (AUC) of combination of FGF21 and testosterone for predicting the occurrence of CAD in men with T2DM was 0.702 (95% CI: 0.667-0.741).

Conclusion: Circulating FGF21 levels were positively associated with CAD in men with T2DM, whereas serum total testosterone levels showed an inverse correlation with CAD in diabetic men.

Citing Articles

Brown adipose tissue-derived FGF21 mediates the cardioprotection of dexmedetomidine in myocardial ischemia/reperfusion injury.

Ding Y, Su J, Shan B, Fu X, Zheng G, Wang J Sci Rep. 2024; 14(1):18292.

PMID: 39112671 PMC: 11306229. DOI: 10.1038/s41598-024-69356-w.

References

Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M . Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013; 12:124. PMC: 3766150. DOI: 10.1186/1475-2840-12-124. View

Liu X, Jiang J, Liu X, Luo Z, Wang Y, Dong X . Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: The Henan Rural Cohort Study. Diabetes Metab Res Rev. 2019; 35(5):e3133. DOI: 10.1002/dmrr.3133. View

Lewis J, Ebling F, Samms R, Tsintzas K . Going Back to the Biology of FGF21: New Insights. Trends Endocrinol Metab. 2019; 30(8):491-504. DOI: 10.1016/j.tem.2019.05.007. View

Zhang J, Li X, Cai Z, Li H, Yang B . Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male. 2019; 23(5):607-618. DOI: 10.1080/13685538.2018.1557139. View

Hui X, Feng T, Liu Q, Gao Y, Xu A . The FGF21-adiponectin axis in controlling energy and vascular homeostasis. J Mol Cell Biol. 2016; 8(2):110-9. DOI: 10.1093/jmcb/mjw013. View

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2020; 44(Suppl 1):S15-S33. DOI: 10.2337/dc21-S002. View

Hotta Y, Kataoka T, Kimura K . Testosterone Deficiency and Endothelial Dysfunction: Nitric Oxide, Asymmetric Dimethylarginine, and Endothelial Progenitor Cells. Sex Med Rev. 2019; 7(4):661-668. DOI: 10.1016/j.sxmr.2019.02.005. View

Geng L, Lam K, Xu A . The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020; 16(11):654-667. DOI: 10.1038/s41574-020-0386-0. View

Kim K, Jeong Y, Oh H, Kim S, Cho J, Kim Y . Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med. 2012; 19(1):83-92. DOI: 10.1038/nm.3014. View

10.

Lorigo M, Mariana M, Lemos M, Cairrao E . Vascular mechanisms of testosterone: The non-genomic point of view. J Steroid Biochem Mol Biol. 2019; 196:105496. DOI: 10.1016/j.jsbmb.2019.105496. View

11.

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

12.

Troncoso M, Pavez M, Wilson C, Lagos D, Duran J, Ramos S . Testosterone activates glucose metabolism through AMPK and androgen signaling in cardiomyocyte hypertrophy. Biol Res. 2021; 54(1):3. PMC: 7863443. DOI: 10.1186/s40659-021-00328-4. View

13.

Wittert G, Bracken K, Robledo K, Grossmann M, Yeap B, Handelsman D . Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2020; 9(1):32-45. DOI: 10.1016/S2213-8587(20)30367-3. View

14.

Zhao S, Li X . The association of low plasma testosterone level with coronary artery disease in Chinese men. Int J Cardiol. 1998; 63(2):161-4. DOI: 10.1016/s0167-5273(97)00295-7. View

15.

Itoh N, Ornitz D . Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004; 20(11):563-9. DOI: 10.1016/j.tig.2004.08.007. View

16.

Zeng Z, Zheng Q, Chen J, Tan X, Li Q, Ding L . FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis. Exp Cell Res. 2020; 393(2):112108. DOI: 10.1016/j.yexcr.2020.112108. View

17.

Richardson P, McKenna W, Bristow M, Maisch B, MAUTNER B, OConnell J . Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996; 93(5):841-2. DOI: 10.1161/01.cir.93.5.841. View

18.

Xiaolong L, Dongmin G, Liu M, Zuo W, Huijun H, Qiufen T . FGF21 induces autophagy-mediated cholesterol efflux to inhibit atherogenesis via RACK1 up-regulation. J Cell Mol Med. 2020; 24(9):4992-5006. PMC: 7205825. DOI: 10.1111/jcmm.15118. View

19.

Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

20.

Adua E, Roberts P, Sakyi S, Yeboah F, Dompreh A, Frimpong K . Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study. Clin Transl Med. 2017; 6(1):32. PMC: 5587509. DOI: 10.1186/s40169-017-0162-5. View